Home Angiogenesis Src inhibitor PP2 For research use only.

PP2

Synonyms: AG 1879,AGL 1879

PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.

PP2 Chemical Structure

PP2 Chemical Structure

CAS No. 172889-27-9

Purity & Quality Control

PP2 Related Products

Signaling Pathway

Src Signaling Pathways

Src Signaling Pathway

Cell Data

Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A549 Growth inhibition assay Growth inhibition of human A549 cells, IC50 = 0.01 μM. 28814374
T-cells Function assay Inhibition of adhesion kinase in human T cells, IC50 = 0.6 μM. 18077363
T-cells Function assay Inhibition of tyrosine phosphorylation in human T cells, IC50 = 0.6 μM. 18077363
SH-SY5Y Antiproliferative assay 72 hrs Antiproliferative activity against human SH-SY5Y cells assessed as cell viability after 72 hrs by XTT assay, IC50 = 6.1 μM. 21856155
Saos2 Cytotoxicity assay 48 hrs Cytotoxicity against human Saos2 cells after 48 hrs by MTT assay, IC50 = 8.07 μM. 23932070
SaOS2 Antiproliferative assay Antiproliferative activity against human SaOS2 cells assessed as cellular viability, IC50 = 8.1 μM. 17929792
A431 Function assay Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21), IC50 = 17 μM. 15109642
MEG01 Antiproliferative assay Antiproliferative activity against human MEG01 cells, IC50 = 17 μM. 18257513
A431 Function assay Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38), IC50 = 22 μM. 15109642
K562 Antiproliferative assay Antiproliferative activity against human K562 cells, IC50 = 25 μM. 18257513
A431 Antiproliferative assay Tested for antiproliferative activity against human A431 cells, IC50 = 32 μM. 15109642
A431 Antiproliferative assay Antiproliferative activity against A431 cells, IC50 = 32.2 μM. 16509573
KU812 Antiproliferative assay Antiproliferative activity against human KU812 cells, IC50 = 45 μM. 18257513
A431 Function assay 10 uM Inhibition of Src autophosphorylation of Y419 in A431 cells at 10 uM 16509573
8701-BC Proapoptotic assay 10 uM Proapoptotic activity against 8701-BC cells at 10 uM by PARP assay 16509573
Click to View More Cell Line Experimental Data

Biological Activity

Description PP2 (AG 1879, AGL 1879), a Src family kinase inhibitor, potently inhibits Lck/Fyn with IC50 of 4 nM/5 nM in cell-free assays, ~100-fold less potent to EGFR, inactive for ZAP-70, JAK2 and PKA.
Targets
LCK [1]
(Cell-free assay)		 Fyn [1]
(Cell-free assay)
4 nM 5 nM
In vitro
In vitro

PP2 inhibits Src by binding to an area of the molecule that does not overlap with the ATP binding domain. [2] PP2 (20 μM) induces 40-50% growth inhibition of HT29 cells, this concentration reduces the Src activity as early as 1 hour and maintains a 35% inhibition of Src activity for 2 days. PP2 (100 mM) decreases the Src activity of HT29 cells in a dose-dependent manner. PP2 (1 mM-100 mM) causes a dose-dependent growth inhibition of human colon cancer cells (HT29, SW480, and PMCO1), liver cancer cells (PLC/PRF/5, KYN-2, Li7, and HepG2), and breast cancer cells (MCF-7, MDA-MB-468, and BT-474). PP2 (20 μM) significantly increases aggregation in most of the cancer cells (HT29, SW480, PMCO1, PLC/PRF/5, KYN-2, Li7, MCF-7, and MDA-MB-468) in E-cadherin dependent manner. PP2 (20 μM) enhances E-cadherin expression and also strongly increases E-cadherin’s association with the actin cytoskeleton in cancer cells. PP2 (20 μM) increases the expression of α-catenin, β-catenin, and γ-catenin in HT29 cells, whereas in PLC/PRF/5 and MCF-7 cells, the total protein level of α-catenin does not change, but the levels of β- catenin and γ-catenin increases slightly. [3] PP2 inhibits proliferation of two cervical cancer cells (HeLa and SiHa) in a time- and dose-dependent manner. PP2 (10 μM) down-regulates pSrc-Y416, pEGFR-Y845, and -Y1173 expression levels in HeLa and SiHa cells. PP2 (10 μM) could modulate cell cycle arrest by up-regulating p21(Cip1) and p27(Kip1) in both HeLa and SiHa cells and down-regulating expression of cyclin A, and cyclin dependent kinase-2, -4 (Cdk-2, -4) in HeLa and of cyclin B and Cdk-2 in SiHa. [4]
Kinase Assay Immune complex enzyme assays
The acid-treated enolase is diluted 1:20 with 1× PBS before aliquoting 100 mL/well into a Nunc 96-well high protein binding assay plate. Assay wells are then aspirated; blocked with 0.5% bovine serum, 1× PBS for 1 h at 37 ℃;and then washed five times with 300 mL of 1× PBS/well. The source of Lck is either LSTRA cells or Lck expressed in HeLa cells using a vaccinia expression system. FynT is expressed in HeLa cells using the vaccinia system. Cells (12.5× 106/mL) are lysed in lysis buffer, and the lysates are clarified by centrifugation at 14,000 cpm for 15 min at 4 ℃ in an Eppendorf tube. The clarified lysates are then incubated with the appropriate anti-kinase antibody at 10 μg/mL for 2 h at 4 ℃. Protein A-Sepharose beads are added to the antibody/lysate mixture at 250 μL/mL and allowed to incubate for 30 min at 4 ℃. The beads are then washed twice in 1 mL of lysis buffer and twice in 1 mL of kinase buffer (25 mM HEPES, 3 mM MnCl2, 5mMMgCl2, and 100 μM sodium orthovanadate) and resuspended to 50% (w/v) in kinase buffer. Twenty-five microliters of the bead suspension is added to each well of the enolase-coated 96-well high protein binding plate together with an appropriate concentration of compound and [γ-32P]ATP (25 μL/well of a 200 μCi/mL solution in kinase buffer). After incubation for 20 min at 20 ℃, 60 μLl of boiling 2× solubilization buffer containing 10 mM ATP is added to the assay wells to terminate the reactions. Thirty microliters of the samples is removed from the wells, boiled for 5 min, and run on a 7.5% SDS-polyacrylamide gel. The gels are subsequently dried and exposed to Kodak X-AR film. For quantitation, films are scanned using a Molecular Dynamics laser scanner, and the optical density of the major substrate band, enolase p46, is determined. In companion experiments for measuring the activity of compounds against Lck, the assay plate is washed with two wash cycles on a Skatron harvester using 50 mM EDTA, 1 mM ATP. Scintillation fluid (100 μL) is then added to the wells, and 32P incorporation is measured using a micro-β-counter.
Cell Research Cell lines HT29, SW480, PMCO1, PLC/PRF/5, KYN-2, Li7, HepG2, MCF-7, MDA-MB-468 and BT-474 cell lines
Concentrations ~100 μM
Incubation Time 2 days
Method

Cell viability is determined using an in vitro toxicology assay kit following the manufacturer’s instructions. Cells are seeded in 96-well plates at day 0. Starting at day 1, cells are treated for 2 days with each of a series of increasing concentrations of PP2 (1 μM, 10 μM, and 100 μM). At the end of this period, cell proliferation is evaluated  by mitochondria dehydrogenase in viable cells, leading to formazan formation. This experiment is repeated three times with 10 determinations/tested concentration.
Experimental Result Images Methods Biomarkers Images PMID
Western blot p-PI3K / PI3K / p-AKT / AKT / Bcl-2 / Caspase-3 p-Src / Src / p-MAPK / MAPK 30250573
Immunofluorescence β-catenin FAK / p-FAK 18566211
In Vivo
In vivo

PP2 (5 mg/kg/day) induces some slowing in the growth rate of the primary tumors relative to the control treated with vehicle in SCID mice inoculated HT29 cells in the spleen. PP2 (5 mg/kg/day) induces some slowing in the growth rate of the primary tumors relative to the control treated with vehicle in SCID mice inoculated HT29 cells in the spleen. PP2 (5 mg/kg/day) significantly reduces the relative liver weight and liver metastasis volume compared with the controls in SCID mice inoculated HT29 cells in the spleen. [3] PP2 (1.5 mg/kg i.p.) treated rats show approximately 50% reduction of infarct size on T2-weighted MRI and in TTC staining compared with controls in rats with focal ischemic brain injury. PP2 (1.5 mg/kg i.p.) results in better the neurological score than controls in rats with focal ischemic brain injury. [5]
Animal Research Animal Models SCID mice inoculated HT29 cells in the spleen
Dosages 5 mg/kg/day
Administration intraperitoneal injection
NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03842371 Unknown status
Sepsis Syndrome
West China Hospital
 February 11 2019 --
NCT02407626 Terminated
Myocardial Ischemia
Triemli Hospital|University of Alberta
 September 2015 Not Applicable
NCT02315287 Unknown status
Type 2 Diabetes
Seoul National University Bundang Hospital
 September 2014 Phase 4

Chemical Information & Solubility

Molecular Weight 301.77 Formula

C15H16ClN5
CAS No. 172889-27-9 SDF Download PP2 SDF
Smiles CC(C)(C)N1C2=NC=NC(=C2C(=N1)C3=CC=C(C=C3)Cl)N
Storage (From the date of receipt)

In vitro
Batch:

DMSO : 60 mg/mL ( (198.82 mM) Moisture-absorbing DMSO reduces solubility. Please use fresh DMSO.)

Ethanol : 2 mg/mL

Water : Insoluble


Molecular Weight Calculator

In vivo
Batch:

Add solvents to the product individually and in order.


In vivo Formulation Calculator

Preparing Stock Solutions

Molarity Calculator

Mass Concentration Volume Molecular Weight

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.

* Indicates a Required Field

Please enter your name.
Please enter your email. Please enter a valid email address.
Please write something to us.

Frequently Asked Questions

Question 1:
Could you please suggest me the in vivo details about the dilution to reduce the amount of DMSO to 1 to 5%?

Answer:
For in vivo study, we recommend to use 4% DMSO +Corn oil up to 2.5 mg/ml.

Tags: buy PP2 | PP2 supplier | purchase PP2 | PP2 cost | PP2 manufacturer | order PP2 | PP2 distributor